Division of Cardiology and Oppenheimer Atherosclerosis Research Center, Cedars-Sinai Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Rev Cardiovasc Med. 2011;12(2):e55-9.
Statins reduce adverse cardiovascular events in both primary and secondary prevention settings. Despite their use, however, a residual burden of cardiovascular events continues to remain; in part this residual risk is related to low high-density lipoprotein (HDL) cholesterol levels. Therefore, HDL-based interventions that either raise HDL cholesterol levels or improve HDL function have become the next target for atherosclerosis management.
他汀类药物可降低一级和二级预防环境中的不良心血管事件。然而，尽管有其应用，心血管事件的残余负担仍然存在；部分残余风险与低高密度脂蛋白（HDL）胆固醇水平有关。因此，基于 HDL 的干预措施，无论是升高 HDL 胆固醇水平还是改善 HDL 功能，都已成为动脉粥样硬化管理的下一个目标。
